![4X5A1130-min-1200x800 4X5A1130-min-1200x800](https://www.abzena.bio/hs-fs/hubfs/4X5A1130-min-1200x800.jpg?width=1200&height=800&name=4X5A1130-min-1200x800.jpg)
One-Pager: Linking Antibody to Drug with ThioBridge®
Enhance Your ADC Development with ThioBridge® Conjugation Technology
Take a look at how Abzena’s ThioBridge® conjugation overcomes issues with existing technologies to give you antibody-drug conjugate (ADCs) with improved stability, potency, and efficacy.
What’s Inside?
While ADCs are a powerful and targeted approach to therapeutics, first-generation conjugation technologies have limitations such as inconsistent drug-to-antibody ratios (DAR) and the risk of early payload detachment. Abzena’s ThioBridge® conjugation technology offers a solution by providing a more uniform DAR profile, stable linker attachment, and improved pharmacokinetic properties.
![Abzena---Thiobridge-Animated-LinkedIn-Graphics-C---1200x628---RGB---v1.1 (1) Abzena---Thiobridge-Animated-LinkedIn-Graphics-C---1200x628---RGB---v1.1 (1)](https://www.abzena.bio/hubfs/Abzena---Thiobridge-Animated-LinkedIn-Graphics-C---1200x628---RGB---v1.1%20(1).gif)